Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Perils of AI-Generated Peer Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.

Lung cancer (Amsterdam, Netherlands)·2025

Related Experiment Video

Updated: May 22, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

MET: a promising anticancer therapeutic target.

Solange Peters1, Alex A Adjei

  • 1Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, CH1011 Lausanne, Switzerland.

Nature Reviews. Clinical Oncology
|May 9, 2012
PubMed
Summary

Targeting the MET pathway shows promise for cancer therapy, but inhibitors offer modest benefits in unselected patients. Future strategies focus on biomarkers and combination therapies for improved outcomes.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Experiment Videos

Last Updated: May 22, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • The MET pathway is frequently dysregulated in human cancers, driving tumor growth, invasion, and metastasis.
  • Aberrant MET signaling is linked to poor prognosis and resistance to cancer treatments, highlighting its therapeutic relevance.
  • MET inhibitors are under clinical investigation, but initial trials show limited efficacy in broad patient groups.

Purpose of the Study:

  • To review the challenges and opportunities in developing MET inhibitors for cancer therapy.
  • To discuss the critical need for predictive biomarkers to guide MET inhibitor treatment.
  • To explore optimal combination strategies involving MET inhibitors and other therapeutic modalities.

Main Methods:

  • Literature review of preclinical and clinical studies on MET inhibitors.
  • Analysis of current challenges in biomarker discovery for MET-targeted therapies.
  • Synthesis of data on combining MET inhibitors with chemotherapy, radiotherapy, and other targeted agents.

Main Results:

  • MET inhibitors represent a promising therapeutic avenue but require careful patient selection for optimal benefit.
  • Identification of predictive biomarkers is crucial for stratifying patients likely to respond to MET-targeted drugs.
  • Combination therapies, including MET inhibitors with other agents, may overcome resistance and enhance treatment efficacy.

Conclusions:

  • Developing effective MET inhibitor therapies necessitates addressing challenges in biomarker identification and combination strategies.
  • Personalized approaches combining MET inhibitors with other treatments hold potential for improving clinical outcomes in cancer patients.